Columnist Caroline Gainer weighs in on how changes with her doctors have affected her ability to coordinate care for her COPD ...

Digital inhalers that allow remote patient monitoring may predict impending exacerbations, or episodes when symptoms of COPD ...

Yupelri (revefenacin) is an approved once-daily maintenance therapy developed by Theravance Biopharma and Mylan (now part of Viatris) for chronic obstructive pulmonary disease (COPD). Its U.S.

COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for ...

COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for ...

No description.Caroline Gainer is from West Virginia, the state with the highest rate of COPD in the United States. She was diagnosed with moderate-to-severe COPD in 2013 after a pneumothorax (lung ...

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer ...

Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder that causes several symptoms which make breathing difficult. These include persistent cough with mucus, wheezing, and shortness ...

Fatigue is one of the most common symptoms of COPD, so it's important to understand what causes it, columnist Caroline Gainer says.

Budesonide for inhalation (brand name, Pulmicort; AstraZeneca) is a corticosteroid used to prevent breathing difficulties, chest tightness, wheezing, and coughing caused by respiratory disorders, such ...

Abrysvo was already cleared in the U.S. for adults older than 60 and pregnant people at 32-36 weeks of gestation to protect infants from birth to age 6 months. With the new authorization, Abrysvo ...

The Verona Pharma therapy, with a list price of $2,950 for a monthly supply, was cleared by the U.S. Food and Drug Administration in June as an inhaled maintenance therapy for adults with COPD. “We ...